Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
复制标题
DOI：
10.1210/jc.2011-1193
复制
发表时间：
2011-07-01
影响因子：
5.8
通讯作者：
Weaver, Connie M.
中科院分区：
文献类型：
--
作者：
Holick, Michael F.;Binkley, Neil C.;Weaver, Connie M.
目的：其目的是提供指导方针，临床医生的评估，治疗和预防维生素D缺乏症的重点是谁是在风险的病人的护理deficiency.Participants：工作队是由一个主席，另外六名专家，和一个方法学家。工作组没有收到公司的资金或报酬。共识过程：共识是在几次电话会议和电子邮件通信中对证据和讨论进行系统审查的指导下达成的。工作组编写的草案先后由内分泌学会临床指南小组委员会、临床事务核心委员会和共同赞助协会审查，并发布在内分泌学会网站上供会员审查。在每个阶段的审查，工作组收到的书面意见，并纳入所需的changes.Conclusions：考虑到维生素D缺乏症是非常常见的，在所有年龄组，很少有食物含有维生素D，工作组建议补充建议的每日摄入量和可耐受的上限水平，根据年龄和临床情况。工作队还建议通过可靠的测定方法测量血清25-羟基维生素D水平，作为有缺乏风险的患者的初步诊断测试。对于缺乏维生素D-2或维生素D-3的患者，建议使用维生素D-2或维生素D-3治疗。目前，还没有足够的证据建议筛查没有缺乏风险的个体，或处方维生素D以获得心血管保护的非钙益处。（临床内分泌代谢杂志96：1911-1930，2011）
Objective: The objective was to provide guidelines to clinicians for the evaluation, treatment, and prevention of vitamin D deficiency with an emphasis on the care of patients who are at risk for deficiency.Participants: The Task Force was composed of a Chair, six additional experts, and a methodologist. The Task Force received no corporate funding or remuneration.Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during several conference calls and e-mail communications. The draft prepared by the Task Force was reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and cosponsoring associations, and it was posted on The Endocrine Society website for member review. At each stage of review, the Task Force received written comments and incorporated needed changes.Conclusions: Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances. The Task Force also suggested the measurement of serum 25-hydroxy vitamin D level by a reliable assay as the initial diagnostic test in patients at risk for deficiency. Treatment with either vitamin D-2 or vitamin D-3 was recommended for deficient patients. At the present time, there is not sufficient evidence to recommend screening individuals who are not at risk for deficiency or to prescribe vitamin D to attain the noncalcemic benefit for cardiovascular protection. (J Clin Endocrinol Metab 96: 1911-1930, 2011)